Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.
Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Their proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, their technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Their Ionic Purification System and Kits combine to provide researchers with a fast, efficient, and effective alternative for automated nucleic acid purification.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 2, 2021 | Series Unknown | $34.44M | — | — | — | Detail |
Jun 12, 2019 | Series B | $26.40M | 4 | Agilent Technologies | — | Detail |
May 17, 2016 | Series A | $18.20M | 3 | 5AM Ventures Roche Venture Fund | — | Detail |
Mar 10, 2016 | Series Unknown | $13.01M | — | — | — | Detail |
Aug 5, 2014 | Debt Financing | $200K | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Agilent Technologies | Yes | Series B |
5AM Ventures | — | Series B |
Cota Capital | — | Series B |
Roche Venture Fund | — | Series B |
StartX (Stanford-StartX Fund) | — | Series A |